Drug developer Pozen (POZN +40%) soars after reporting late Wednesday that it sold the U.S....

|By:, SA News Editor

Drug developer Pozen (POZN +40%) soars after reporting late Wednesday that it sold the U.S. royalty rights from its migraine drug Treximet to Canada's national pension fund, CPPIB Credit Investments.